ClinicalTrials.gg
CompletedNCT01459926Updated May 22, 2026

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

A Phase 2 interventional study of TD-1211 and TD-1211 in Opioid Induced Constipation, sponsored by Glycyx Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Glycyx Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Opioid-Induced Constipation with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Opioid-Induced Constipation · United States.

Enrollment
21st of 40
217 · median 227
Started
2011
with 9 others
Phase 2
12 of 43
none open now
Registered
32nd of 43
by date
Lead sponsor
6 of 43
Glycyx Therapeutics

Among the 43 studies in Opioid-Induced Constipation with a site in United States, this one is the 21st largest by enrollment of the 40 interventional ones that give a count, is one of 10 that started in 2011, is one of 12 in phase 2, and was the 32nd registered.

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

Browse Opioid-Induced Constipation studies →

Open to participants now

1 of the 43 studies in Opioid-Induced Constipation with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Opioid-Induced Constipation studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Opioid-Induced Constipation with a site in United States, or all of them as a file.
02

Study summary

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation

03

Conditions studied

  • Opioid Induced Constipation

Keywords

  • Opioid induced constipation
  • OIC
  • Constipation
  • Opioid side effects
  • Morphine induced constipation
  • Opioid therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of constipation with onset after initiation of opioid therapy
  • Self-reported OIC of approximately 3 spontaneous bowel movements (SBMs) per week or less for each week over at least the previous two week period
  • Have used chronic opioids with a total daily dose ≥30 mg of morphine equivalent units (MEU, Appendix 7) for the 12 weeks preceding the Screening Visit. Subjects should have used a stable daily regimen of opioids for at least the 2 weeks preceding the Screening Visit
  • Willing to stop all laxatives and other bowel regimens with the exception of bisacodyl/enema treatment allowed per protocol throughout the OIC confirmation, treatment, and follow-up periods

Exclusion criteria

Exclusion Criteria:

  • Have participated in a clinical trial of an drug or medical device within 30 days prior to Screening
  • Have any condition that may affect drug absorption, (e.g., previous GI surgery)
  • Any other condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety or tolerability of the investigational drug, or prevent compliance with the study protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Dose 1

    Drug: TD-1211

  • Experimental
    Dose 2

    Drug: TD-1211

  • Experimental
    Dose 3

    Drug: TD-1211

  • Experimental
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the weekly average CSBMs over Weeks 2 to 5 of treatment

    Time frame: Between weeks 2 and 5

Secondary outcomes

  1. Change from baseline in the weekly SBM frequency in the last week of treatment

    Time frame: baseline and 5 weeks

07

Study locations

1 site
  • G and L Research, LLC
    Foley, Alabama 36535, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of May 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Oct 26, 2011
Start
Nov 2011
Primary completionActual
May 2012
CompletionActual
Jun 2012
Results delay requested
Jun 5, 2013
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01459926
Lead sponsor
Glycyx Therapeutics
Responsible party
Sponsor
First posted
Oct 26, 2011
Start date
Nov 2011
Primary completion
May 2012
Completion
Jun 2012
Last update
May 22, 2026

Study contacts

Medical Monitor
study director · Theravance Biopharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axelopran

Start the discussion